Znanstveni rad - Izvorni znanstveni rad
Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
Croatian Medical Journal, 63 (2022), 2; 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, Snježana; Paić, Frane; Smajlbegović, Velda; Perić Balja, Melita; Hiršl, Lea; Marton, Ingrid; Knežević, Fabijan

Citirajte ovaj rad

Ramić, S., Paić, F., Smajlbegović, V., Perić Balja, M., Hiršl, L., Marton, I. i Knežević, F. (2022). Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal, 63. (2), 126-140. doi: 10.3325/cmj.2022.63.126

Ramić, Snježana, et al. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal, vol. 63, br. 2, 2022, str. 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, Snježana, Frane Paić, Velda Smajlbegović, Melita Perić Balja, Lea Hiršl, Ingrid Marton i Fabijan Knežević. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal 63, br. 2 (2022): 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, S., et al. (2022) 'Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients', Croatian Medical Journal, 63(2), str. 126-140. doi: 10.3325/cmj.2022.63.126

Ramić S, Paić F, Smajlbegović V, Perić Balja M, Hiršl L, Marton I, i sur.. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal [Internet]. 30.04.2022. [pristupljeno 09.08.2022.];63(2):126-140. doi: 10.3325/cmj.2022.63.126

S. Ramić, et al., "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients", Croatian Medical Journal, vol. 63, br. 2, str. 126-140, Travanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:519799. [Citirano: 09.08.2022.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.